Glaxosmithkline Drug Patent Portfolio
Glaxosmithkline owns 21 orange book drugs protected by 128 US patents with Blujepa having the least patent protection, holding only 1 patent. And Ventolin Hfa with maximum patent protection, holding 35 patents. Given below is the list of Glaxosmithkline's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11963962 | Platelet count-agnostic methods of treating myelofibrosis | 02 Dec, 2040 | Active |
| US11730725 | Niraparib formulations | 25 Jan, 2039 | Active |
| US11091459 | Niraparib compositions | 27 Mar, 2038 | Active |
| US11673877 | Niraparib compositions | 27 Mar, 2038 | Active |
| US11117871 | Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof | 13 Mar, 2038 | Active |
| US11649217 | Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof | 13 Mar, 2038 | Active |
| US9809559 | (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide | 11 Jun, 2035 | Active |
| USRE48285 | N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide | 11 Jun, 2035 | Active |
| US8859562 | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer | 04 Aug, 2031 | Active |
| US8746242 | Medicament dispenser | 11 Apr, 2031 | Active |
| US8071623 | Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors | 27 Mar, 2031 | Active |
| US11090294 | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist | 29 Nov, 2030 | Active |
| US9750726 | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist | 29 Nov, 2030 | Active |
| US8746242 | Medicament dispenser | 11 Oct, 2030 | Active |
| US8534281 | Manifold for use in medicament dispenser | 08 Sep, 2030 | Active |
| US8534281 | Manifold for use in medicament dispenser | 08 Mar, 2030 | Active |
| US8486941 | Phenyl amino pyrimidine compounds and uses thereof | 03 Jan, 2030 | Active |
| US8436185 | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide | 24 Apr, 2029 | Active |
| US8389524 | Tricyclic nitrogen containing compounds as antibacterial agents | 12 Feb, 2029 | Active |
| US8201556 | Medicament dispenser | 05 Feb, 2029 | Active |
| US8324208 | Prolyl hydroxylase inhibitors | 11 Dec, 2028 | Active |
| US8161968 | Medicament dispenser | 05 Aug, 2028 | Active |
| US8113199 | Counter for use with a medicament dispenser | 23 Apr, 2028 | Active |
| US9333310 | Medicament dispenser | 02 Apr, 2028 | Active |
| US8161968 | Medicament dispenser | 05 Feb, 2028 | Active |
| US7488827 | Muscarinic acetylcholine receptor antagonists | 18 Dec, 2027 | Active |
| US8511304 | Medicament dispenser | 14 Dec, 2027 | Active |
| US8113199 | Counter for use with a medicament dispenser | 23 Oct, 2027 | Active |
| US9333310 | Medicament dispenser | 02 Oct, 2027 | Active |
| US8071579 | DNA damage repair inhibitors for the treatment of cancer | 12 Aug, 2027 | Active |
| US8143241 | DNA damage repair inhibitors for treatment of cancer | 12 Aug, 2027 | Active |
| US11643397 | Prolyl hydroxylase inhibitors | 22 Jun, 2027 | Active |
| US8557834 | Prolyl hydroxylase inhibitors | 22 Jun, 2027 | Active |
| US8815884 | Prolyl hydroxylase inhibitors | 22 Jun, 2027 | Active |
| US8511304 | Medicament dispenser | 14 Jun, 2027 | Active |
| US8347879 | Fluid dispensing device | 01 Apr, 2027 | Active |
| US8062264 | Fluid dispensing device | 05 Apr, 2026 | Active |
| US8752543 | Fluid dispensing device | 05 Apr, 2026 | Active |
| US7439393 | Phenethanolamine derivatives for treatment of respiratory diseases | 21 Nov, 2025 | Active |
| US8183257 | Muscarinic acetylcholine receptor antagonists | 27 Jul, 2025 | Active |
| US7500444 | Actuation indicator for a dispensing device | 04 Jul, 2025 | Active |
| US7439393 | Phenethanolamine derivatives for treatment of respiratory diseases | 21 May, 2025 | Expired |
| US7498440 | Muscarinic acetylcholine receptor antagonists | 27 Apr, 2025 | Expired |
| US8309572 | Muscarinic acetylcholine receptor antagonists | 27 Apr, 2025 | Expired |
| US8147461 | Fluid dispensing device | 10 Mar, 2025 | Expired |
| US7500444 | Actuation indicator for a dispensing device | 04 Jan, 2025 | Expired |
| US9320862 | Fluid dispensing device | 06 Nov, 2024 | Expired |
| US7832351 | Actuation indicator for a dispensing device | 19 Dec, 2023 | Expired |
| US7832351 | Actuation indicator for a dispensing device | 19 Jun, 2023 | Expired |
| US7361787 | Phenethanolamine derivatives for treatment of respiratory diseases | 23 Mar, 2023 | Expired |
| USRE44874 | Phenethanolamine derivatives for treatment of respiratory diseases | 23 Mar, 2023 | Expired |
| US7776895 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases | 11 Sep, 2022 | Expired |
| US6743413 | Suspension aerosol formulations | 01 Dec, 2021 | Expired |
| US7101866 | Anti-inflammatory androstane derivative | 03 Aug, 2021 | Expired |
| US7629335 | Anti-inflammatory androstane derivative | 03 Aug, 2021 | Expired |
| US6537983 | Anti-inflammatory androstane derivatives | 03 Aug, 2021 | Expired |
| US6759398 | Anti-inflammatory androstane derivative | 03 Aug, 2021 | Expired |
| US6878698 | Anti-inflammatory androstane derivatives | 03 Aug, 2021 | Expired |
| US6858596 | Formulation containing anti-inflammatory androstane derivative | 03 Aug, 2021 | Expired |
| US7541350 | Formulation containing anti-inflammatory androstane derivative | 03 Aug, 2021 | Expired |
| US6743413 | Suspension aerosol formulations | 01 Jun, 2021 | Expired |
| US9861771 | Device housing for an aerosol container | 11 Oct, 2020 | Expired |
| US7350676 | Valve for aerosol container | 24 Feb, 2019 | Expired |
| US6431168 | Dispenser with doses′ counter | 08 Dec, 2018 | Expired |
| US7107986 | Dispenser with doses' counter | 06 Dec, 2018 | Expired |
| US6004968 | Pharmaceutical compositions containing lamivudine | 20 Sep, 2018 | Expired |
| US7350676 | Valve for aerosol container | 24 Aug, 2018 | Expired |
| US6161724 | Indicating device | 16 Jul, 2018 | Expired |
| US6435372 | Delivery system for a medicament and method for the assembly thereof | 16 Jul, 2018 | Expired |
| US6938796 | Indicating device | 16 Jul, 2018 | Expired |
| US6997349 | Indicating device | 16 Jul, 2018 | Expired |
| US7143908 | Indicating device | 16 Jul, 2018 | Expired |
| US6170717 | Valve for aerosol container | 23 Jun, 2018 | Expired |
| US6315173 | Valve for aerosol container | 23 Jun, 2018 | Expired |
| US6510969 | Valve for aerosol container | 23 Jun, 2018 | Expired |
| US6966467 | Valve for aerosol container | 23 Jun, 2018 | Expired |
| US6431168 | Dispenser with doses′ counter | 08 Jun, 2018 | Expired |
| US7107986 | Dispenser with doses' counter | 08 Jun, 2018 | Expired |
| US6004968 | Pharmaceutical compositions containing lamivudine | 20 Mar, 2018 | Expired |
| US6161724 | Indicating device | 16 Jan, 2018 | Expired |
| US6435372 | Delivery system for a medicament and method for the assembly thereof | 16 Jan, 2018 | Expired |
| US6938796 | Indicating device | 16 Jan, 2018 | Expired |
| US6997349 | Indicating device | 16 Jan, 2018 | Expired |
| US7143908 | Indicating device | 16 Jan, 2018 | Expired |
| US6170717 | Valve for aerosol container | 23 Dec, 2017 | Expired |
| US6315173 | Valve for aerosol container | 23 Dec, 2017 | Expired |
| US6510969 | Valve for aerosol container | 23 Dec, 2017 | Expired |
| US6966467 | Valve for aerosol container | 23 Dec, 2017 | Expired |
| US6730679 | Pharmaceutical formulations | 11 Nov, 2017 | Expired |
| US6558651 | Aerosols containing annealed particulate salbutamol and tetrafluoroethane | 19 Jun, 2017 | Expired |
| US6558651 | Aerosols containing annealed particulate salbutamol and tetrafluoroethane | 19 Dec, 2016 | Expired |
| US5905082 | Crystalline oxathiolane derivatives | 18 Nov, 2016 | Expired |
| US5873360 | Inhalation device | 23 Aug, 2016 | Expired |
| US5879706 | Valaciclovir tablets containing colloidal silicon dioxide | 19 Jul, 2016 | Expired |
| US6107302 | Guanine derivative | 19 Jul, 2016 | Expired |
| US5905082 | Crystalline oxathiolane derivatives | 18 May, 2016 | Expired |
| US5873360 | Inhalation device | 23 Feb, 2016 | Expired |
| US5879706 | Valaciclovir tablets containing colloidal silicon dioxide | 19 Jan, 2016 | Expired |
| US6107302 | Guanine derivative | 19 Jan, 2016 | Expired |
| US5723490 | THF-containing sulfonamide inhibitors of aspartyl protease | 03 Mar, 2015 | Expired |
| US6596260 | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol | 10 Feb, 2015 | Expired |
| US6294572 | Crystalline N-acetyl neuraminic acid derivatives and process for their preparation | 15 Dec, 2014 | Expired |
| US6025389 | Pharmaceutical and veterinary compositions of mupirocin and methods for their preparation | 20 Oct, 2014 | Expired |
| US6596260 | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol | 10 Aug, 2014 | Expired |
| US5648379 | Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents | 15 Jul, 2014 | Expired |
| US5646180 | Treatment of the CNS effects of HIV | 08 Jul, 2014 | Expired |
| US5998449 | Combination of atovaquone with proguanil for the treatment of protozoal infections | 25 May, 2014 | Expired |
| US6166046 | Combination of atovaquone with proguanil for the treatment of protozoal infections | 25 May, 2014 | Expired |
| US6291488 | Preventing protozoal infections | 25 May, 2014 | Expired |
| US5629297 | Medicament for treating gastrointestinal disorders | 13 May, 2014 | Expired |
| US5554639 | Medicaments | 10 Mar, 2014 | Expired |
| US5601848 | Methods for the treatment of gastrointestinal disorders | 11 Feb, 2014 | Expired |
| USRE39155 | Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B | 02 Jan, 2014 | Expired |
| US5585397 | Sulfonamide inhibitors of aspartyl protease | 17 Dec, 2013 | Expired |
| US5998449 | Combination of atovaquone with proguanil for the treatment of protozoal infections | 25 Nov, 2013 | Expired |
| US6166046 | Combination of atovaquone with proguanil for the treatment of protozoal infections | 25 Nov, 2013 | Expired |
| US6291488 | Preventing protozoal infections | 25 Nov, 2013 | Expired |
| US5569672 | Compounds | 29 Oct, 2013 | Expired |
| US5554639 | Medicaments | 10 Sep, 2013 | Expired |
| US5358970 | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer | 12 Aug, 2013 | Expired |
| US5427798 | Controlled sustained release tablets containing bupropion | 12 Aug, 2013 | Expired |
| US5731000 | Stabilized pharmaceutical composition containing bupropion | 12 Aug, 2013 | Expired |
| US5763493 | Stabilized pharmaceutical | 12 Aug, 2013 | Expired |
| US5360817 | Derivatives and analogues of 2-deoxy-2,3-didehydro-N-acetyl neuraminic acid and their use as antiviral agents | 26 Jul, 2013 | Expired |
| USRE39155 | Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B | 02 Jul, 2013 | Expired |
| US5307953 | Single dose dispenser having a piercing member | 02 Jun, 2013 | Expired |
| US5307953 | Single dose dispenser having a piercing member | 02 Dec, 2012 | Expired |
| US5456925 | Pharmaceutical compositions containing furan derivatives | 10 Oct, 2012 | Expired |
Latest Legal Activities on Glaxosmithkline's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Glaxosmithkline.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Second letter to regulating agency to determine regulatory review period | 26 Apr, 2024 | US8324208 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 Apr, 2024 | US8309572 |
|
Email Notification
Critical
| 13 Feb, 2024 | US11730725 |
| Mail Pet Dec Routed to Certificate of Corrections Branch | 12 Feb, 2024 | US11730725 |
| Mail-Record a Petition Decision of Granted for Patent Term Adjustment after Issue | 12 Feb, 2024 | US11730725 |
| Record a Petition Decision of Granted for Patent Term Adjustment after Issue | 09 Feb, 2024 | US11730725 |
| Pet Dec Routed to Certificate of Corrections Branch | 09 Feb, 2024 | US11730725 |
| Adjustment of PTA Calculation by PTO | 09 Feb, 2024 | US11730725 |
| Second letter to regulating agency to determine regulatory review period | 08 Feb, 2024 | US8486941 |
| Letter from FDA or Dept of Agriculture re PTE application | 30 Jan, 2024 | US8324208 |
| Letter from FDA or Dept of Agriculture re PTE application | 30 Jan, 2024 | US8486941 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Nov, 2023 | US8201556 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Nov, 2023 | US8201556 |
| Initial letter Re: PTE Application to regulating agency | 17 Nov, 2023 | US8486941 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 01 Nov, 2023 | US8486941 |
Glaxosmithkline's Drug Patent Litigations
Glaxosmithkline's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 26, 2001, against patent number US6596260. The petitioner , challenged the validity of this patent, with BRUGGER et al as the respondent. Click below to track the latest information on how companies are challenging Glaxosmithkline's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6743413 | September, 2015 |
Terminated-Settled
(18 Nov, 2016)
| 3M Company | Mylan Pharmaceuticals Inc. |
| US8859562 | October, 2011 |
Decision
(25 Mar, 2014)
| Thomas Helleday | |
| US6596260 | July, 2001 |
Decision
(25 Sep, 2002)
| BRUGGER et al | |
Glaxosmithkline Drug Patents' Oppositions Filed in EPO
Glaxosmithkline drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 13, 2012, by Strawman Limited. This opposition was filed on patent number EP04743564A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP06765149A | Apr, 2020 | ELKINGTON AND FIFE LLP | Patent maintained as amended |
| EP10781527A | Sep, 2018 | Sima Patent ve Lisanslama Hizmetleri Ltd.Sti. | Granted and Under Opposition |
| EP10781527A | Sep, 2018 | Breuer, Markus | Granted and Under Opposition |
| EP10781527A | Sep, 2018 | Teva UK Limited | Granted and Under Opposition |
| EP10178947A | Jun, 2015 | Teva UK Limited | Revoked |
| EP03731693A | May, 2014 | Teva UK Limited | Opposition rejected |
| EP03731693A | May, 2014 | Vossius & Partner | Opposition rejected |
| EP04798705A | May, 2012 | Adams, Harvey Vaughan John | Opposition procedure closed |
| EP04798705A | May, 2012 | STRAWMAN LIMITED | Opposition procedure closed |
| EP04743564A | Apr, 2012 | Adams, Harvey Vaughan John | Patent maintained as amended |
| EP04743564A | Apr, 2012 | STRAWMAN LIMITED | Patent maintained as amended |
Glaxosmithkline's Family Patents
Glaxosmithkline Drug List
Given below is the complete list of Glaxosmithkline's drugs and the patents protecting them.
1. Agenerase
Agenerase is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6730679 | Pharmaceutical formulations |
11 Nov, 2017
(7 years ago)
| Expired |
| US5723490 | THF-containing sulfonamide inhibitors of aspartyl protease |
03 Mar, 2015
(10 years ago)
| Expired |
| US5646180 | Treatment of the CNS effects of HIV |
08 Jul, 2014
(10 years ago)
| Expired |
| US5585397 | Sulfonamide inhibitors of aspartyl protease |
17 Dec, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Agenerase's drug page
2. Anoro Ellipta
Anoro Ellipta is protected by 25 patents, out of which 7 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8746242
(Pediatric)
| Medicament dispenser |
11 Apr, 2031
(5 years from now)
| Active |
| US11090294 | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
29 Nov, 2030
(5 years from now)
| Active |
| US9750726 | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
29 Nov, 2030
(5 years from now)
| Active |
| US8746242 | Medicament dispenser |
11 Oct, 2030
(5 years from now)
| Active |
| US8534281
(Pediatric)
| Manifold for use in medicament dispenser |
08 Sep, 2030
(5 years from now)
| Active |
| US8534281 | Manifold for use in medicament dispenser |
08 Mar, 2030
(4 years from now)
| Active |
| US8201556 | Medicament dispenser |
05 Feb, 2029
(3 years from now)
| Active |
| US8161968
(Pediatric)
| Medicament dispenser |
05 Aug, 2028
(3 years from now)
| Active |
| US8113199
(Pediatric)
| Counter for use with a medicament dispenser |
23 Apr, 2028
(2 years from now)
| Active |
| US9333310
(Pediatric)
| Medicament dispenser |
02 Apr, 2028
(2 years from now)
| Active |
| US8161968 | Medicament dispenser |
05 Feb, 2028
(2 years from now)
| Active |
| US7488827 | Muscarinic acetylcholine receptor antagonists |
18 Dec, 2027
(2 years from now)
| Active |
| US8511304
(Pediatric)
| Medicament dispenser |
14 Dec, 2027
(2 years from now)
| Active |
| US8113199 | Counter for use with a medicament dispenser |
23 Oct, 2027
(2 years from now)
| Active |
| US9333310 | Medicament dispenser |
02 Oct, 2027
(2 years from now)
| Active |
| US8511304 | Medicament dispenser |
14 Jun, 2027
(1 year, 11 months from now)
| Active |
| US7439393
(Pediatric)
| Phenethanolamine derivatives for treatment of respiratory diseases |
21 Nov, 2025
(4 months from now)
| Active |
| US8183257 | Muscarinic acetylcholine receptor antagonists |
27 Jul, 2025
(24 days from now)
| Active |
| US7439393 | Phenethanolamine derivatives for treatment of respiratory diseases |
21 May, 2025
(a month ago)
| Expired |
| US7498440 | Muscarinic acetylcholine receptor antagonists |
27 Apr, 2025
(2 months ago)
| Expired |
| US8309572 | Muscarinic acetylcholine receptor antagonists |
27 Apr, 2025
(2 months ago)
| Expired |
| US7361787 | Phenethanolamine derivatives for treatment of respiratory diseases |
23 Mar, 2023
(2 years ago)
| Expired |
| USRE44874 | Phenethanolamine derivatives for treatment of respiratory diseases |
23 Mar, 2023
(2 years ago)
| Expired |
| US7776895 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases |
11 Sep, 2022
(2 years ago)
| Expired |
| US5873360 | Inhalation device |
23 Feb, 2016
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Anoro Ellipta's drug page
3. Arnuity Ellipta
Arnuity Ellipta is protected by 14 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8746242
(Pediatric)
| Medicament dispenser |
11 Apr, 2031
(5 years from now)
| Active |
| US8746242 | Medicament dispenser |
11 Oct, 2030
(5 years from now)
| Active |
| US8534281
(Pediatric)
| Manifold for use in medicament dispenser |
08 Sep, 2030
(5 years from now)
| Active |
| US8534281 | Manifold for use in medicament dispenser |
08 Mar, 2030
(4 years from now)
| Active |
| US8201556 | Medicament dispenser |
05 Feb, 2029
(3 years from now)
| Active |
| US8161968
(Pediatric)
| Medicament dispenser |
05 Aug, 2028
(3 years from now)
| Active |
| US8113199
(Pediatric)
| Counter for use with a medicament dispenser |
23 Apr, 2028
(2 years from now)
| Active |
| US9333310
(Pediatric)
| Medicament dispenser |
02 Apr, 2028
(2 years from now)
| Active |
| US8161968 | Medicament dispenser |
05 Feb, 2028
(2 years from now)
| Active |
| US8113199 | Counter for use with a medicament dispenser |
23 Oct, 2027
(2 years from now)
| Active |
| US9333310 | Medicament dispenser |
02 Oct, 2027
(2 years from now)
| Active |
| US7101866 | Anti-inflammatory androstane derivative |
03 Aug, 2021
(3 years ago)
| Expired |
| US7629335 | Anti-inflammatory androstane derivative |
03 Aug, 2021
(3 years ago)
| Expired |
| US5873360 | Inhalation device |
23 Feb, 2016
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Arnuity Ellipta's drug page
4. Bactroban
Bactroban is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6025389 | Pharmaceutical and veterinary compositions of mupirocin and methods for their preparation |
20 Oct, 2014
(10 years ago)
| Expired |
| US5569672 | Compounds |
29 Oct, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bactroban's drug page
5. Blujepa
Blujepa is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8389524 | Tricyclic nitrogen containing compounds as antibacterial agents |
12 Feb, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Blujepa's drug page
Explore Our Curated Drug Screens
6. Epivir-hbv
Epivir-hbv is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6004968
(Pediatric)
| Pharmaceutical compositions containing lamivudine |
20 Sep, 2018
(6 years ago)
| Expired |
| US6004968 | Pharmaceutical compositions containing lamivudine |
20 Mar, 2018
(7 years ago)
| Expired |
| US5905082
(Pediatric)
| Crystalline oxathiolane derivatives |
18 Nov, 2016
(8 years ago)
| Expired |
| US5905082 | Crystalline oxathiolane derivatives |
18 May, 2016
(9 years ago)
| Expired |
| USRE39155
(Pediatric)
| Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B |
02 Jan, 2014
(11 years ago)
| Expired |
| USRE39155 | Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B |
02 Jul, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epivir-hbv's drug page
7. Imitrex
Imitrex is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5554639
(Pediatric)
| Medicaments |
10 Mar, 2014
(11 years ago)
| Expired |
| US5554639 | Medicaments |
10 Sep, 2013
(11 years ago)
| Expired |
| US5307953
(Pediatric)
| Single dose dispenser having a piercing member |
02 Jun, 2013
(12 years ago)
| Expired |
| US5307953 | Single dose dispenser having a piercing member |
02 Dec, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Imitrex's drug page
8. Jesduvroq
Jesduvroq is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11117871 | Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof |
13 Mar, 2038
(12 years from now)
| Active |
| US11649217 | Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof |
13 Mar, 2038
(12 years from now)
| Active |
| US8324208 | Prolyl hydroxylase inhibitors |
11 Dec, 2028
(3 years from now)
| Active |
| US11643397 | Prolyl hydroxylase inhibitors |
22 Jun, 2027
(1 year, 11 months from now)
| Active |
| US8557834 | Prolyl hydroxylase inhibitors |
22 Jun, 2027
(1 year, 11 months from now)
| Active |
| US8815884 | Prolyl hydroxylase inhibitors |
22 Jun, 2027
(1 year, 11 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jesduvroq's drug page
9. Malarone
Malarone is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5998449
(Pediatric)
| Combination of atovaquone with proguanil for the treatment of protozoal infections |
25 May, 2014
(11 years ago)
| Expired |
| US6166046
(Pediatric)
| Combination of atovaquone with proguanil for the treatment of protozoal infections |
25 May, 2014
(11 years ago)
| Expired |
| US6291488
(Pediatric)
| Preventing protozoal infections |
25 May, 2014
(11 years ago)
| Expired |
| US5998449 | Combination of atovaquone with proguanil for the treatment of protozoal infections |
25 Nov, 2013
(11 years ago)
| Expired |
| US6166046 | Combination of atovaquone with proguanil for the treatment of protozoal infections |
25 Nov, 2013
(11 years ago)
| Expired |
| US6291488 | Preventing protozoal infections |
25 Nov, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Malarone's drug page
10. Malarone Pediatric
Malarone Pediatric is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5998449
(Pediatric)
| Combination of atovaquone with proguanil for the treatment of protozoal infections |
25 May, 2014
(11 years ago)
| Expired |
| US6166046
(Pediatric)
| Combination of atovaquone with proguanil for the treatment of protozoal infections |
25 May, 2014
(11 years ago)
| Expired |
| US6291488
(Pediatric)
| Preventing protozoal infections |
25 May, 2014
(11 years ago)
| Expired |
| US5998449 | Combination of atovaquone with proguanil for the treatment of protozoal infections |
25 Nov, 2013
(11 years ago)
| Expired |
| US6166046 | Combination of atovaquone with proguanil for the treatment of protozoal infections |
25 Nov, 2013
(11 years ago)
| Expired |
| US6291488 | Preventing protozoal infections |
25 Nov, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Malarone Pediatric's drug page
11. Ojjaara
Ojjaara is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11963962 | Platelet count-agnostic methods of treating myelofibrosis |
02 Dec, 2040
(15 years from now)
| Active |
| US9809559 | (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide |
11 Jun, 2035
(9 years from now)
| Active |
| USRE48285 | N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide |
11 Jun, 2035
(9 years from now)
| Active |
| US8486941 | Phenyl amino pyrimidine compounds and uses thereof |
03 Jan, 2030
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ojjaara's drug page
12. Relenza
Relenza is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6294572 | Crystalline N-acetyl neuraminic acid derivatives and process for their preparation |
15 Dec, 2014
(10 years ago)
| Expired |
| US5648379 | Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents |
15 Jul, 2014
(10 years ago)
| Expired |
| US5360817 | Derivatives and analogues of 2-deoxy-2,3-didehydro-N-acetyl neuraminic acid and their use as antiviral agents |
26 Jul, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Relenza's drug page
13. Serevent
Serevent is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5873360
(Pediatric)
| Inhalation device |
23 Aug, 2016
(8 years ago)
| Expired |
| US5873360 | Inhalation device |
23 Feb, 2016
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Serevent's drug page
14. Trelegy Ellipta
Trelegy Ellipta is protected by 27 patents, out of which 10 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8746242
(Pediatric)
| Medicament dispenser |
11 Apr, 2031
(5 years from now)
| Active |
| US11090294 | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
29 Nov, 2030
(5 years from now)
| Active |
| US9750726 | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
29 Nov, 2030
(5 years from now)
| Active |
| US8746242 | Medicament dispenser |
11 Oct, 2030
(5 years from now)
| Active |
| US8534281
(Pediatric)
| Manifold for use in medicament dispenser |
08 Sep, 2030
(5 years from now)
| Active |
| US8534281 | Manifold for use in medicament dispenser |
08 Mar, 2030
(4 years from now)
| Active |
| US8161968
(Pediatric)
| Medicament dispenser |
05 Aug, 2028
(3 years from now)
| Active |
| US8113199
(Pediatric)
| Counter for use with a medicament dispenser |
23 Apr, 2028
(2 years from now)
| Active |
| US9333310
(Pediatric)
| Medicament dispenser |
02 Apr, 2028
(2 years from now)
| Active |
| US8161968 | Medicament dispenser |
05 Feb, 2028
(2 years from now)
| Active |
| US7488827 | Muscarinic acetylcholine receptor antagonists |
18 Dec, 2027
(2 years from now)
| Active |
| US8511304
(Pediatric)
| Medicament dispenser |
14 Dec, 2027
(2 years from now)
| Active |
| US8113199 | Counter for use with a medicament dispenser |
23 Oct, 2027
(2 years from now)
| Active |
| US9333310 | Medicament dispenser |
02 Oct, 2027
(2 years from now)
| Active |
| US8511304 | Medicament dispenser |
14 Jun, 2027
(1 year, 11 months from now)
| Active |
| US7439393
(Pediatric)
| Phenethanolamine derivatives for treatment of respiratory diseases |
21 Nov, 2025
(4 months from now)
| Active |
| US8183257 | Muscarinic acetylcholine receptor antagonists |
27 Jul, 2025
(24 days from now)
| Active |
| US7439393 | Phenethanolamine derivatives for treatment of respiratory diseases |
21 May, 2025
(a month ago)
| Expired |
| US7498440 | Muscarinic acetylcholine receptor antagonists |
27 Apr, 2025
(2 months ago)
| Expired |
| US8309572 | Muscarinic acetylcholine receptor antagonists |
27 Apr, 2025
(2 months ago)
| Expired |
| USRE44874 | Phenethanolamine derivatives for treatment of respiratory diseases |
23 Mar, 2023
(2 years ago)
| Expired |
| US7776895 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases |
11 Sep, 2022
(2 years ago)
| Expired |
| US6537983 | Anti-inflammatory androstane derivatives |
03 Aug, 2021
(3 years ago)
| Expired |
| US6759398 | Anti-inflammatory androstane derivative |
03 Aug, 2021
(3 years ago)
| Expired |
| US6878698 | Anti-inflammatory androstane derivatives |
03 Aug, 2021
(3 years ago)
| Expired |
| US7101866 | Anti-inflammatory androstane derivative |
03 Aug, 2021
(3 years ago)
| Expired |
| US7629335 | Anti-inflammatory androstane derivative |
03 Aug, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trelegy Ellipta's drug page
15. Tritec
Tritec is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5629297 | Medicament for treating gastrointestinal disorders |
13 May, 2014
(11 years ago)
| Expired |
| US5601848 | Methods for the treatment of gastrointestinal disorders |
11 Feb, 2014
(11 years ago)
| Expired |
| US5456925 | Pharmaceutical compositions containing furan derivatives |
10 Oct, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tritec's drug page
16. Valtrex
Valtrex is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5879706
(Pediatric)
| Valaciclovir tablets containing colloidal silicon dioxide |
19 Jul, 2016
(8 years ago)
| Expired |
| US6107302
(Pediatric)
| Guanine derivative |
19 Jul, 2016
(8 years ago)
| Expired |
| US5879706 | Valaciclovir tablets containing colloidal silicon dioxide |
19 Jan, 2016
(9 years ago)
| Expired |
| US6107302 | Guanine derivative |
19 Jan, 2016
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Valtrex's drug page
17. Ventolin Hfa
Ventolin Hfa is protected by 35 patents, out of which 34 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7500444
(Pediatric)
| Actuation indicator for a dispensing device |
04 Jul, 2025
(a day from now)
| Active |
| US7500444 | Actuation indicator for a dispensing device |
04 Jan, 2025
(5 months ago)
| Expired |
| US7832351
(Pediatric)
| Actuation indicator for a dispensing device |
19 Dec, 2023
(1 year, 6 months ago)
| Expired |
| US7832351 | Actuation indicator for a dispensing device |
19 Jun, 2023
(2 years ago)
| Expired |
| US6743413
(Pediatric)
| Suspension aerosol formulations |
01 Dec, 2021
(3 years ago)
| Expired |
| US6743413 | Suspension aerosol formulations |
01 Jun, 2021
(4 years ago)
| Expired |
| US9861771 | Device housing for an aerosol container |
11 Oct, 2020
(4 years ago)
| Expired |
| US7350676
(Pediatric)
| Valve for aerosol container |
24 Feb, 2019
(6 years ago)
| Expired |
| US6431168
(Pediatric)
| Dispenser with doses′ counter |
08 Dec, 2018
(6 years ago)
| Expired |
| US7107986
(Pediatric)
| Dispenser with doses' counter |
06 Dec, 2018
(6 years ago)
| Expired |
| US7350676 | Valve for aerosol container |
24 Aug, 2018
(6 years ago)
| Expired |
| US6161724
(Pediatric)
| Indicating device |
16 Jul, 2018
(6 years ago)
| Expired |
| US6435372
(Pediatric)
| Delivery system for a medicament and method for the assembly thereof |
16 Jul, 2018
(6 years ago)
| Expired |
| US6938796
(Pediatric)
| Indicating device |
16 Jul, 2018
(6 years ago)
| Expired |
| US6997349
(Pediatric)
| Indicating device |
16 Jul, 2018
(6 years ago)
| Expired |
| US7143908
(Pediatric)
| Indicating device |
16 Jul, 2018
(6 years ago)
| Expired |
| US6170717
(Pediatric)
| Valve for aerosol container |
23 Jun, 2018
(7 years ago)
| Expired |
| US6315173
(Pediatric)
| Valve for aerosol container |
23 Jun, 2018
(7 years ago)
| Expired |
| US6510969
(Pediatric)
| Valve for aerosol container |
23 Jun, 2018
(7 years ago)
| Expired |
| US6966467
(Pediatric)
| Valve for aerosol container |
23 Jun, 2018
(7 years ago)
| Expired |
| US6431168 | Dispenser with doses′ counter |
08 Jun, 2018
(7 years ago)
| Expired |
| US7107986 | Dispenser with doses' counter |
08 Jun, 2018
(7 years ago)
| Expired |
| US6161724 | Indicating device |
16 Jan, 2018
(7 years ago)
| Expired |
| US6435372 | Delivery system for a medicament and method for the assembly thereof |
16 Jan, 2018
(7 years ago)
| Expired |
| US6938796 | Indicating device |
16 Jan, 2018
(7 years ago)
| Expired |
| US6997349 | Indicating device |
16 Jan, 2018
(7 years ago)
| Expired |
| US7143908 | Indicating device |
16 Jan, 2018
(7 years ago)
| Expired |
| US6170717 | Valve for aerosol container |
23 Dec, 2017
(7 years ago)
| Expired |
| US6315173 | Valve for aerosol container |
23 Dec, 2017
(7 years ago)
| Expired |
| US6510969 | Valve for aerosol container |
23 Dec, 2017
(7 years ago)
| Expired |
| US6966467 | Valve for aerosol container |
23 Dec, 2017
(7 years ago)
| Expired |
| US6558651
(Pediatric)
| Aerosols containing annealed particulate salbutamol and tetrafluoroethane |
19 Jun, 2017
(8 years ago)
| Expired |
| US6558651 | Aerosols containing annealed particulate salbutamol and tetrafluoroethane |
19 Dec, 2016
(8 years ago)
| Expired |
| US6596260
(Pediatric)
| Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
10 Feb, 2015
(10 years ago)
| Expired |
| US6596260 | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
10 Aug, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ventolin Hfa's drug page
18. Veramyst
Veramyst is protected by 8 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8347879 | Fluid dispensing device |
01 Apr, 2027
(1 year, 8 months from now)
| Active |
| US8062264 | Fluid dispensing device |
05 Apr, 2026
(9 months from now)
| Active |
| US8752543 | Fluid dispensing device |
05 Apr, 2026
(9 months from now)
| Active |
| US8147461 | Fluid dispensing device |
10 Mar, 2025
(3 months ago)
| Expired |
| US9320862 | Fluid dispensing device |
06 Nov, 2024
(7 months ago)
| Expired |
| US6858596 | Formulation containing anti-inflammatory androstane derivative |
03 Aug, 2021
(3 years ago)
| Expired |
| US7101866 | Anti-inflammatory androstane derivative |
03 Aug, 2021
(3 years ago)
| Expired |
| US7541350 | Formulation containing anti-inflammatory androstane derivative |
03 Aug, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Veramyst's drug page
19. Wellbutrin Sr
Wellbutrin Sr is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5358970 | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
12 Aug, 2013
(11 years ago)
| Expired |
| US5427798 | Controlled sustained release tablets containing bupropion |
12 Aug, 2013
(11 years ago)
| Expired |
| US5731000 | Stabilized pharmaceutical composition containing bupropion |
12 Aug, 2013
(11 years ago)
| Expired |
| US5763493 | Stabilized pharmaceutical |
12 Aug, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Wellbutrin Sr's drug page
20. Zejula
Zejula is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11730725 | Niraparib formulations |
25 Jan, 2039
(13 years from now)
| Active |
| US11091459 | Niraparib compositions |
27 Mar, 2038
(12 years from now)
| Active |
| US11673877 | Niraparib compositions |
27 Mar, 2038
(12 years from now)
| Active |
| US8859562 | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
04 Aug, 2031
(6 years from now)
| Active |
| US8071623 | Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors |
27 Mar, 2031
(5 years from now)
| Active |
| US8436185 | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide |
24 Apr, 2029
(3 years from now)
| Active |
| US8071579 | DNA damage repair inhibitors for the treatment of cancer |
12 Aug, 2027
(2 years from now)
| Active |
| US8143241 | DNA damage repair inhibitors for treatment of cancer |
12 Aug, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zejula's drug page
21. Zyban
Zyban is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5358970 | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
12 Aug, 2013
(11 years ago)
| Expired |
| US5427798 | Controlled sustained release tablets containing bupropion |
12 Aug, 2013
(11 years ago)
| Expired |
| US5731000 | Stabilized pharmaceutical composition containing bupropion |
12 Aug, 2013
(11 years ago)
| Expired |
| US5763493 | Stabilized pharmaceutical |
12 Aug, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zyban's drug page